Friday, 14 Dec 2018

You are here

RheumNow Live Vote:
Venous Thromboembolism Risk in RA
The risk of Venous-Thromboembolic Events (in my practice) is usually due to:
Which Drugs are associated with a higher VTE risk:
An FDA hearing on 4/23/18 will examine the VTE risk with baricitinib; this risk is:
Would a VT Event on a biologic or JAK cause you to stop that drug?
I am a rheumatologist

RheumNow Live Vote:
Venous Thromboembolism Risk in RA

The risk of Venous-Thromboembolic Events (in my practice) is usually due to:
Which Drugs are associated with a higher VTE risk:
An FDA hearing on 4/23/18 will examine the VTE risk with baricitinib; this risk is:
Would a VT Event on a biologic or JAK cause you to stop that drug?
I am a rheumatologist


Rheumatologists' Comments

Comment: 
I still remain concerned that VTE risk in RA patients is more related to comorbidities than the "chronic inflammatory state" associated with RA.
Comment: 
“Appears to be class effect for oral jak inhibitors” Low rates for tofa, bari, and low rates albeit numerically higher than placebo for filgotinib, upadacitinib1 RR increase VTE rate in RA: 40% Brigham & Women’s RR increase VTE rate in Rheum Diseases: 3 x higher than general population (Arth Res Ther 2014 meta-analysis) Genovese. Rheumatology News. March 15, 2108